Hemin | Hemin chloride;protohemin;Chloro(protoporphyrinato)iron(III), Chlorohemin, Chloroprotoporphyrin IX iron(III), Ferriprotoporphyrin IX chloride, Hemin(chloride) | 氯化血红素 | Other Compounds

首页 / 药物研究 / 小分子阳性药 / 其他化合物 / Hemin/血晶素

Hemin/血晶素 {[allProObj[0].p_purity_real_show]}

货号：A124131 同义名： 氯化血红素 / Hemin chloride; protohemin

Hemin is endogenously produced protoporphyrin IX containing a ferric iron.

Hemin/血晶素化学结构
CAS号：16009-13-5

Hemin/血晶素 3D分子结构
CAS号：16009-13-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Hemin/血晶素纯度/质量文件产品仅供科研

货号：A124131 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

Hemin/血晶素生物活性

描述

In parallel research, Hemin and PGJ2 serve as potent inducers of HMOX expression and activity after 4 and 12 hours, respectively. Particularly, Hemin at 30 μM significantly inhibits cell proliferation in various cancer cell lines (PA-TU-8902, BxPC-3, and MiaPaCa-2) in a dose-dependent manner after 48 hours, with proliferation rates dropping to 62±5%, 51±3%, and 38±8% respectively, and with statistical significance (p<0.0001) across all comparisons. Additionally, Hemin is shown to enhance the anti-proliferative effects of statins, as evidenced by further decreased cell proliferation upon 48 hours of co-treatment^[1].

Hemin/血晶素动物研究

Animal study

Following intraperitoneal (i.p.) administration of Hemin at a dose of 100 μmol/kg, the level of HO-1 in the renal cortex begins to increase gradually, peaking 24 hours after preconditioning. HO-1 expression is primarily observed in the renal tubules, whereas the level of HO-2 in the kidney remains unchanged post-Hemin preconditioning^[2].

Hemin/血晶素临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01817530	Heavy Uterine Bleeding ... 展开 >> Uterine Fibroids 收起 <<	Phase 2	Completed	-	-
NCT03086681	Cervical Carcinoma	Phase 3	Not yet recruiting	February 2020	China, Guangxi ... 展开 >> First Affiliated Hospital of Guangxi Medical University Not yet recruiting Nanning, Guangxi, China, 530021 Contact: Yong Zhang, M.D. 0086-13607884001 zhangyonggx@163.com Contact: Fang Wu, M.D. Sub-Investigator: Jian Li, M.D. Sub-Investigator: Hemin Lu, M.D. Sub-Investigator: Haixin Huang, Master Sub-Investigator: Zhanxiong Luo, Master Sub-Investigator: Meilian Liu, Master Sub-Investigator: Gaojuan Lin, Master Sub-Investigator: Sihui Liao, bachelor Sub-Investigator: Hongqian Wang, bachelor 收起 <<
NCT00307801	Metrorrhagia	Phase 3	Completed	-	-

Hemin/血晶素参考文献

[1]Vanova K, et al. Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. BMC Cancer. 2016 May 12;16:309.

[2]Chen HH, et al. Heme oxygenase-1 ameliorates kidney ischemia-reperfusion injury in mice through extracellular signal-regulated kinase 1/2-enhanced tubular epithelium proliferation. Biochim Biophys Acta. 2015 Oct;1852(10 Pt A):2195-201.

Hemin/血晶素实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.53mL

0.31mL

0.15mL

7.67mL

1.53mL

0.77mL

15.34mL

3.07mL

1.53mL

Hemin/血晶素技术信息

CAS号	16009-13-5
分子式	C₃₄H₃₂ClFeN₄O₄
分子量	651.94
SMILES Code	[Cl-][Fe+3]123[N-]4C5=C(CCC([O-])=O)C(C)=C4C=C(C(C=C)=C6C)[N]1=C6C=C(C(C=C)=C7C)[N-]2C7=CC(C(C)=C8CCC([O-])=O)=[N]3C8=C5.[H+].[H+]
MDL No.	MFCD00010726

别名	氯化血红素 ;Hemin chloride; protohemin; Chloro(protoporphyrinato)iron(III), Chlorohemin, Chloroprotoporphyrin IX iron(III), Ferriprotoporphyrin IX chloride, Hemin(chloride)
运输	蓝冰
InChI Key	BTIJJDXEELBZFS-UHFFFAOYSA-K
Pubchem ID	455658

存储条件	In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry,2-8°C

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01817530	Heavy Uterine Bleeding ... 展开 >> Uterine Fibroids 收起 <<	Phase 2	Completed	-	-
NCT03086681	Cervical Carcinoma	Phase 3	Not yet recruiting	February 2020	China, Guangxi ... 展开 >> First Affiliated Hospital of Guangxi Medical University Not yet recruiting Nanning, Guangxi, China, 530021 Contact: Yong Zhang, M.D. 0086-13607884001 zhangyonggx@163.com Contact: Fang Wu, M.D. Sub-Investigator: Jian Li, M.D. Sub-Investigator: Hemin Lu, M.D. Sub-Investigator: Haixin Huang, Master Sub-Investigator: Zhanxiong Luo, Master Sub-Investigator: Meilian Liu, Master Sub-Investigator: Gaojuan Lin, Master Sub-Investigator: Sihui Liao, bachelor Sub-Investigator: Hongqian Wang, bachelor 收起 <<
NCT00307801	Metrorrhagia	Phase 3	Completed	-	-
NCT00293059	Metrorrhagia	Phase 3	Completed	-	-
NCT00307801	-		Completed	-	-
NCT03338816	Acute Hepatic Porphyria ... 展开 >> Acute Intermittent Porphyria Porphyria, Acute Intermittent Acute Porphyria Hereditary Coproporphyria (HCP) Variegate Porphyria (VP) ALA Dehydratase Deficient Porphyria (ADP) 收起 <<	Phase 3	Active, not recruiting	September 2021	-
NCT02949830	Acute Intermittent Porphyria	Phase 1 Phase 2	Active, not recruiting	August 2020	United States, California ... 展开 >> Clinical Trial Site San Francisco, California, United States United States, New York Clinical Trial Site New York, New York, United States United States, Texas Clinical Trial Site Galveston, Texas, United States Sweden Clinical Trial Site Stockholm, Sweden United Kingdom Clinical Trial Site London, United Kingdom 收起 <<
NCT00293059	-		Completed	-	-
NCT02082860	Acute Intermittent Porphyria	Phase 1	Completed	-	Spain ... 展开 >> Clinica Universidad de Navarra Pamplona, Navarra, Spain, 31008 12 Octubre Hospital Madrid, Spain, 28041 收起 <<
NCT01504308	Uterine Fibroids	Phase 2 Phase 3	Terminated(It was not possible... 展开 >> to enroll patients into the study in a realistic timeframe.) 收起 <<	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, Oregon Oregon Science and Health University Portland, Oregon, United States, 97239 United States, Tennessee Vanderbilt Medical Center Nashville, Tennessee, United States, 37232 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75235 St. Luke's Episcopal Hospital Houston, Texas, United States, 77030 Canada, Ontario Sunnybrook Health Sciences Centre Toronto, Ontario, Canada Korea, Republic of Samsung Medical Center Seoul, Korea, Republic of 收起 <<
NCT01735812	Symptomatic Uterine Fibroids	Not Applicable	Unknown	-	Israel ... 展开 >> Assaf Harofe Recruiting Zrifin, Israel, 70300 Contact: Moty Pansky, Prof. Principal Investigator: Moty Pansky, Prof 收起 <<
NCT02985541	Contraception	Phase 3	Active, not recruiting	June 4, 2021	-
NCT02654054	Uterine Fibroids ... 展开 >> Heavy Menstrual Bleeding 收起 <<	Phase 3	Active, not recruiting	December 19, 2018	-
NCT02794467	Adenomyosis	Phase 2	Withdrawn(Study was prematurel... 展开 >>y discontinued due to GSK's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction.) 收起 <<	October 2016	United States, District of Col... 展开 >>umbia GSK Investigational Site Washington, DC, District of Columbia, United States, 20036 United States, Florida GSK Investigational Site West Palm Beach, Florida, United States, 33409 United States, Illinois GSK Investigational Site Champaign, Illinois, United States, 61820 United States, Louisiana GSK Investigational Site Mandeville, Louisiana, United States, 70471 GSK Investigational Site Metairie, Louisiana, United States, 70006 United States, Nebraska GSK Investigational Site Lincoln, Nebraska, United States, 68510 United States, Nevada GSK Investigational Site Las Vegas, Nevada, United States, 89128 United States, New Jersey GSK Investigational Site Lawrenceville, New Jersey, United States, 08648 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27713 GSK Investigational Site Raleigh, North Carolina, United States, 27612 United States, Ohio GSK Investigational Site Englewood, Ohio, United States, 45322 United States, Pennsylvania GSK Investigational Site Pittsburgh, Pennsylvania, United States, 15206 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 收起 <<
NCT01569763	Menorrhagia	Not Applicable	Completed	-	United States, Arizona ... 展开 >> New Horizons Women's Care Chandler, Arizona, United States, 85224 Women's Health Research Phoenix, Arizona, United States, 85015 United States, Indiana Basinski, LLC Newburgh, Indiana, United States, 47630 United States, Kansas Cypress Medical Research Center, LLC Wichita, Kansas, United States, 67226 United States, Minnesota Minnesota Gynecology and Surgery Edina, Minnesota, United States, 55435 United States, Missouri Mercy Clinic Minimally Invasive Gynecology Saint Louis, Missouri, United States, 63141 United States, Tennessee Tennessee Women's Care PC Nashville, Tennessee, United States, 37203 United States, Texas Baylor Research Institute Fort Worth, Texas, United States, 76104 Canada, Ontario McMaster University/Hamilton Health Sciences Hamilton, Ontario, Canada, L8N3Z5 Canada, Quebec Hôpital LaSalle Ville Lassalle, Quebec, Canada, H8P 1C1 Canada, Saskatchewan Regina Qu'Appelle Health Region Regina, Saskatchewan, Canada, S4S 6X3 Canada La Cite Medicale Quebec, Canada, G1W 2J5 Mexico Hospital Universitario, UANL Monterrey, Nuevo Leon, Mexico, 64460 收起 <<
NCT01199159	Hysterectomy	Not Applicable	Completed	-	Hong Kong ... 展开 >> University of Hong Kong Hong Kong, Hong Kong 收起 <<
NCT03271489	Heavy Menstrual Bleeding ... 展开 >> Uterine Fibroids 收起 <<	Phase 3	Recruiting	May 16, 2022	-
NCT03049735	Heavy Menstrual Bleeding ... 展开 >> Uterine Fibroid 收起 <<	Phase 3	Active, not recruiting	December 30, 2019	-
NCT03412890	Heavy Menstrual Bleeding ... 展开 >> Uterine Fibroid 收起 <<	Phase 3	Enrolling by invitation	July 30, 2020	United States, Arizona ... 展开 >> Mesa Mesa, Arizona, United States, 85209 United States, Colorado Denver Denver, Colorado, United States, 80209 United States, Florida Margate Margate, Florida, United States, 33063 United States, Louisiana Metairie Metairie, Louisiana, United States, 70001 United States, Nevada Las Vegas Las Vegas, Nevada, United States, 89128 United States, Ohio Englewood Englewood, Ohio, United States, 45322 United States, Texas Houston Houston, Texas, United States, 77054 收起 <<
NCT01675011	-		Terminated(Inadequate enrollme... 展开 >>nt) 收起 <<	-	-
NCT01569763	-		Completed	-	-
NCT01276964	-		Unknown	September 2012	Italy ... 展开 >> University of L'Aquila Recruiting L'aquila, Italy, 67100 Contact: napolitano marysanta@libero.it Principal Investigator: napolitano mariasanta, md University of Palermo Active, not recruiting Palermo, Italy, 90127 Casa Sollievo Della Sofferenza Irccs Recruiting San Giovanni Rotondo, Italy, 71013 Contact: grandone grandone@katamail.com Principal Investigator: elvira grandone, md 收起 <<
NCT02076763	-		Completed	-	Spain ... 展开 >> Clinica Universidad de Navarra Pamplona, Navarra, Spain, 31008 12 Octubre Hospital Madrid, Spain, 28041 收起 <<
NCT02691494	Uterine Fibroids ... 展开 >> Heavy Menstrual Bleeding 收起 <<	Phase 3	Active, not recruiting	January 16, 2019	-
NCT01675011	Uterine Fibroids	Not Applicable	Terminated(Inadequate enrollme... 展开 >>nt) 收起 <<	-	United States, New York ... 展开 >> Albany Medical Center Albany, New York, United States North Shore LIJ Medical Center New Hyde Park, New York, United States 收起 <<
NCT01715025	Menorrhagia	Phase 4	Unknown	August 2015	Australia, New South Wales ... 展开 >> SCRHR Recruiting Sydney, New South Wales, Australia, 2131 Principal Investigator: Edith Weisberg, MB BS MM 收起 <<
NCT03103087	Heavy Menstrual Bleeding ... 展开 >> Uterine Fibroid 收起 <<	Phase 3	Active, not recruiting	February 28, 2020	-
NCT03070951	Uterine Fibroids ... 展开 >> Heavy Menstrual Bleeding 收起 <<	Phase 3	Recruiting	November 2019	-
NCT02925494	Uterine Fibroids ... 展开 >> Heavy Menstrual Bleeding 收起 <<	Phase 3	Active, not recruiting	April 8, 2019	-
NCT02131662	Leiomyoma	Phase 2	Completed	-	-
NCT03751124	Uterine Leiomyoma ... 展开 >> Uterine Fibroids 收起 <<	Phase 3	Enrolling by invitation	March 31, 2021	United States, Florida ... 展开 >> United States, Florida West Palm Beach, Florida, United States, 33409 收起 <<
NCT02131662	-		Completed	-	-
NCT02935400	-		Enrolling by invitation	December 2021	United States, Texas ... 展开 >> University of Texas Medical Branch Galveston, Texas, United States, 77555 收起 <<
NCT02180412	Acute Porphyrias	Phase 2	Recruiting	August 31, 2020	United States, Texas ... 展开 >> University of Texas Medical Branch Recruiting Galveston, Texas, United States, 77555 Contact: Karl E Anderson, MD 409-772-4661 kanderso@utmb.edu Contact: Csilla Hallberg, MD 409-772-4661 challberg@utmb.edu Principal Investigator: Karl E Anderson, MD 收起 <<
NCT00467610	-		Terminated(lack of efficacy.)	-	-
NCT03070899	Uterine Fibroids ... 展开 >> Heavy Menstrual Bleeding 收起 <<	Phase 3	Recruiting	February 2020	-
NCT01430156	Graft Failure ... 展开 >> Ischemia-reperfusion Injury 收起 <<	Phase 3	Completed	-	United Kingdom ... 展开 >> Royal Infirmary of Edinburgh/ University of Edinburgh Edinburgh, Lothian, United Kingdom, EH16 4TJ 收起 <<
NCT01206582	Gastroparesis ... 展开 >> Diabetes Mellitus 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55901 收起 <<
NCT00882804	Healthy Volunteers	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT01206582	-		Completed	-	-
NCT01855841	Post-ERCP Acute Pancreatitis	Phase 2	Recruiting	February 2019	Belgium ... 展开 >> CHU Brugmann Terminated Brussels, Belgium, 1020 Erasme Hospital, Université Libre de Bruxelles (ULB) Recruiting Brussels, Belgium, 1070 Contact: Arnaud Lemmers, MD, PhD +3225556559 arnaud.lemmers@erasme.ulb.ac.be Contact: Mohammed Amrani +3225558382 mohammed.amrani@erasme.ulb.ac.be Principal Investigator: Arnaud Lemmers, MD, PhD Sub-Investigator: Olivier Le Moine, MD, PhD Sub-Investigator: Jacques Devière, MD, PhD Sub-Investigator: Myriam Delhaye, MD, PhD Sub-Investigator: Marianna Arvanitakis, MD, PhD Centre Hospitalier de Jolimont-Lobbes Recruiting Haine-St-Paul, Belgium, 7100 Contact: Didier Verset, MD +32 478 421 493 didier.verset@skynet.be Principal Investigator: Didier Verset, MD CHU Liège Sart Tilman Not yet recruiting Liège, Belgium, 4000 Contact: Jean-Philippe Loly, MD 04/366.74.39 jp.loly@hotmail.com Contact: Wertz Sylvie 04/366.74.39 swertz@chu.ulg.ac.be Hôpital Ambroise Paré Recruiting Mons, Belgium, 7000 Contact: Axel Hittelet, MD 065.39.37.48 axel.hittelet@hap.be Principal Investigator: Axel Hittelet, MD ISPPC CHU Vésale Terminated Montigny Le tilleul, Belgium, 6110 Italy San Raffaele Scientific Institute, Vita Salute San Raffaele University Not yet recruiting Milan, Italy, 20132 Contact: MariaChiara Petrone, MD petrone.mariachiara@hsr.it Principal Investigator: MariaChiara Petrone, MD Policlinico Gemelli Universita Cattolica Not yet recruiting Rome, Italy, 00168 Contact: Guido Costamagna, MD 06.35511515 gcostamagna@rm.unicatt.it Principal Investigator: Guido Costamagna, MD Sub-Investigator: Andrea Tringali, MD Taiwan National Taiwan University Hospital Recruiting Taipei, Taiwan Contact: Wei-Chih Liao, MD,PhD david.ntuh@gmail.com Principal Investigator: Wei-Chih Liao, MD,PhD 收起 <<
NCT00467610	Myelodysplastic Syndrome	Phase 2	Terminated(lack of efficacy.)	-	United States, Illinois ... 展开 >> Rush University Medical Center Chicago, Illinois, United States, 60612 收起 <<
NCT02922413	Acute Intermittent Porphyria ... 展开 >> Hereditary Coproporphyria Variegate Porphyria 收起 <<	Phase 2	Recruiting	September 2021	United States, Texas ... 展开 >> University of Texas Medical Branch Recruiting Galveston, Texas, United States, 77555 Contact: Karl E Anderson, MD 409-772-4661 kanderso@utmb.edu Contact: Csilla Hallberg, MD 409-772-4661 ext 24661 ckhallbe@UTMB.EDU 收起 <<

Hemin/血晶素 {[allProObj[0].p_purity_real_show]}

Hemin/血晶素纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Hemin/血晶素质控信息

Hemin/血晶素生物活性

Hemin/血晶素动物研究

Hemin/血晶素临床研究

Hemin/血晶素参考文献

Hemin/血晶素实验方案

Hemin/血晶素技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Hemin/血晶素 {[allProObj[0].p_purity_real_show]}

Hemin/血晶素 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Hemin/血晶素 质控信息

Hemin/血晶素 生物活性

Hemin/血晶素 动物研究

Hemin/血晶素 临床研究

Hemin/血晶素 参考文献

Hemin/血晶素 实验方案

Hemin/血晶素 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Hemin/血晶素纯度/质量文件产品仅供科研

Hemin/血晶素质控信息

Hemin/血晶素生物活性

Hemin/血晶素动物研究

Hemin/血晶素临床研究

Hemin/血晶素参考文献

Hemin/血晶素实验方案

Hemin/血晶素技术信息